This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Add Chemed (CHE) to Your Portfolio Now
by Zacks Equity Research
Chemed (CHE) continues to ride high on strength in Roto-Rooter business.
Bio-Rad (BIO) at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Bio-Rad (BIO) consistently invests in R&D for product innovation.
BioTelemetry Ties Up With Apple, Grows in Cardiac Monitoring
by Zacks Equity Research
BioTelemetry (BEAT) is consistently trying to improve its position in the cardiac monitoring and diagnostic services space.
Flexion's (FLXN) Zilretta Therapy to Fast Capture OA Market
by Zacks Equity Research
Flexion's (FLXN) commercial launch of Zilretta seems well-timed keeping in view how rapidly the osteoarthritis market is growing worldwide.
Veeva Systems (VEEV) Grows in Digital Asset Management Space
by Zacks Equity Research
Veeva Systems' (VEEV) constant endeavors seem to boost the Veeva Vault portfolio.
Genomic Health-Cleveland Diagnostics Deal to Boost Test Suite
by Zacks Equity Research
Genomic Health (GHDX) forges ahead with deals to strengthen hold in the high-potential prostate cancer therapeutics market.
GNC Holdings Grapples With Margin Weakness, Stiff Competition
by Zacks Equity Research
Weak margins, declining year-over-year revenues and rising operating costs continue to pose challenges to GNC Holdings (GNC).
LabCorp's Covance Business Bounces Back on Chiltern Buyout
by Zacks Equity Research
Despite a dull show for several quarters, LabCorp's (LH) Covance Drug Development reported strong growth in the third quarter, courtesy of Chiltern acquisition. However, volume woes remain.
Align Technology (ALGN) Grows on InvisAlign System Strength
by Zacks Equity Research
Align Technology (ALGN) continues to gain from strength in the InvisAlign space.
Edwards Lifesciences' Pipeline Strong Amid Rising Expenses
by Zacks Equity Research
Edwards Lifesciences' (EW) aim at building its pipeline to fortify foothold across all operating businesses augurs well for the company. However, higher operating expenses are a concern.
Patterson Companies Dental Business Dull, Competition Rife
by Zacks Equity Research
Patterson's (PDCO) dental segment sales have been weak. The company faces stiff competition from at least 15 full-service distributors and small distributors.
Align Teams Up with Exocad to Expand in Digital Scanning
by Zacks Equity Research
Align's (ALGN) collaboration with CAD/CAM software provider, Exocad GmbH, is likely to integrate the Chairside CAD software into Align's iTero Element intraoral scanner.
Hologic (HOLX) Focuses on Breast Health, Ties Up with Clarius
by Zacks Equity Research
Hologic (HOLX) forges ahead with its efforts to strengthen hold in the high potential breast cancer screening market.
Hologic's FDA Nod for Quantra Software Boosts Breast Health
by Zacks Equity Research
Hologic (HOLX) is consistently trying to boost its Breast Health segment.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) continues to grow on innovation and product launches.
Luminex (LMNX) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Luminex (LMNX) gains from recent FDA approvals and product launches.
Zimmer Biomet Hurt by Supply Delay, Knee Challenges Remain
by Zacks Equity Research
Zimmer Biomet (ZBH) struggles with supply delay problem related to some of its products, causing inability to win back lost customers and gain new ones.
AmerisourceBergen to Take Over H. D. Smith for $815 Million
by Zacks Equity Research
AmerisourceBergen (ABC) strives to strengthen core businesses. The H. D. Smith buyout is likely to strengthen the Pharmaceutical Distribution Segment.
Rising Costs Hurt Henry Schein, End-Market Trends a Tailwind
by Zacks Equity Research
Higher cost of sales and expenses hurt Henry Schein's (HSIC) gross and operating margin. However, several end market trends like demographics are likely to benefit the company.
Teladoc, Inc. (TDOC) Jumps: Stock Rises 10.5%
by Zacks Equity Research
Teladoc, Inc. (TDOC) was a big mover last session, as the company saw its shares nearly 11/% on the day amid huge volumes.
Medtronic Wins FDA Nod for Azure Pacemakers, Grows in CVG
by Zacks Equity Research
Medtronic (MDT) strives to improve its Cardiac Rhythm and Heart Failure division.
DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) renewed distribution deal will help the company gain market traction. However, forex woes remain a concern.
McKesson Gains From Distribution Business Amid Pricing Woes
by Zacks Equity Research
McKesson Corporation's (MCK) Distribution business is driven by market growth and acquisitions. However, pricing remains a concern.
Haemonetics (HAE) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Haemonetics (HAE) focuses on development and launch of NexSys PCS plasmapheresis system.